New drug cocktail aims to fight recurrent head and neck cancer
NCT ID NCT06668961
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase II trial is testing whether two experimental drugs (SI-B001 and SI-B003) plus standard chemotherapy can help people with head and neck cancer that has come back or spread. About 60 adults aged 18 to 75 will receive the combination as their first treatment. The main goal is to see how many patients' tumors shrink or disappear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SI-B001 and SI-B003 (investigational drugs) combined with platinum-based chemotherapy
What this could lead to
If successful, this combination could offer a new first-line treatment option for people with recurrent or metastatic head and neck cancer, potentially shrinking tumors and delaying disease progression.
What could go wrong
This is an early Phase II trial with only 60 participants, so results may not apply to everyone. The drugs are experimental, and side effects from the combination could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact